Please assess the completion status of the following clinical trial:

Trial Title: A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of non-resectable adenocarcinoma of the biliary tract, including carcinomas of the gallbladder, the intrahepatic or extrahepatic biliary tract, and ampullary cancer~* Measurable or evaluable disease~* Locally advanced disease that is inoperable ot patients who have had disease recurrence after curative surgical attempt~* Ambulatory with an ECOG performance status of 0-1~* Adequate organ and marrow function~* Must agree to avoid pregnancy prior to study entry and throughout the duration of study participation~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Any prior chemotherapy~* Patients who are receiving other investigational agents~* Patients who have received radiotherapy to more than 25% of their bone marrow for any reason~* Peripheral neuropathy \>/= 2~* Known brain metastases, uncontrolled seizure disorder, encephalitis~* Prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled hypertension,unstable angina, congestive heart failure of New York Heart Association (NYHA) class 2 or greater, left ventricular ejection fraction less than 50%, clinically significant vascular disease, serious cardiac arrhythmia requiring medication, cardiomyopathy~* History of myocardial infarction, unstable angina or stroke/transient ischemic attack (TIA) within 6 months~* History of allergy to oxaliplatin, 5-fluoruracil (5-FU), Leucovorin, or Bevacizumab~* History of intra-abdominal abscess within 4 weeks of study entry, abdominal fistula, gastrointestinal perforation, active peptic ulcer disease, or inflammatory bowel disease~* Evidence of bleeding diathesis or coagulopathy~* Serious non-healing wound, ulcer, or bone fracture~* Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks of study entry or anticipation of need for major surgery during the course of the study~* Minor surgical procedures such as core biopsies within 7 days before enrollment, chemotherapy port placement within 24 hours~* Patients on full-dose anticoagulants who have out of range international normalized ratio (INR) or active bleeding~* Concurrent malignancy unless the subject has been curatively treated and disease free for \>/= 2 years or the cancer was non-melanoma skin cancer or early cervical cancer~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements~* Known HIV or Hepatitis B or C~* Life expectancy less than 12 weeks~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFOX6 and Bevacizumab (Type: EXPERIMENTAL): Intervention = bevacizumab in combination with chemotherapy~Treatment of biliary system carcinoma using Bevacizumab in combination with modified FOLFOX6.

Based on this trial design, predict the completion outcome and termination type (if applicable).